ArticleClinical ophthalmology (Auckland, N.Z.)2026
Short-Term Choroidal and Retinal Structural Changes in Myopic Children Treated with 0.05% Atropine.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate daily 0.05% atropine's effects on structural changes in the choroid and retina in myopic children. Methods: This prospective cohort study included 100 children aged 6-15 years, of whom 83 completed 6-month follow-up. Participants received either nightly 0.05% atropine eyedrops or no pharmacologic treatment (all wore single-vision spectacles). Spherical equivalent (SE) and axial length (AL) were measured, and swept-source OCT angiography was used to assess choroidal thickness (CT), retinal thickness (RT), outer retinal layer (ORL), ganglion cell layer plus inner plexiform layer (GCL+IPL), inner nuclear layer (INL), peripapillary retinal nerve fiber layer (RNFL), choroidal vascular volume (CVV), choroidal vascular index (CVI), superficial and deep vascular complexes (SVC/DVC), and nerve fiber layer vascular density (NFVD). Results: Atropine reduced myopia progression compared to controls (ΔSE: 0.11 vs -0.30 D; ΔAL: 0.01 vs 0.17 mm; Conclusion: Daily 0.05% atropine not only slowed myopia progression and axial elongation but also promoted thickening of choroidal and retinal layers. These structural changes suggest partial reversal of ocular growth, supporting the therapeutic role of atropine in myopia control. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2100043506, https://www.chictr.org.cn/showproj.html?proj=122214, registered 21 February 2021). This study represents a secondary analysis of the registered trial; the control group was drawn from an ethically approved observational cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.